BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • BCI
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, July 2, 2026
Breaking News: Science fiction realized: BCI tech is hereBreaking News: Science fiction realized: BCI tech is hereBreaking News: Science fiction realized: BCI tech is here
Home » Topics » BioWorld Science

BioWorld Science
BioWorld Science RSS Feed RSS

Neurology/psychiatric

Vandria’s series A funds spur development of mitophagy inducer

Aug. 22, 2024
By Nuala Moran
After sparking further interest from investors after the close of its series A, Vandria SA has extended the round and now has the means to advance its lead mitophagy inducer program as far as phase Ib/IIa development in the treatment of mild cognitive impairment.
Read More

Other news to note for Aug. 21, 2024

Aug. 21, 2024
Additional early-stage research and drug discovery news in brief, from: Inmed Pharmaceuticals.
Read More
Cardiovascular

Opna Bio discovers new YAP1/TEAD interaction inhibitors

Aug. 21, 2024
Opna Bio AG has described transcriptional coactivator YAP1/transcriptional enhancer factor (TEAD) interaction inhibitors reported to be useful for the treatment of arrhythmogenic right ventricular cardiomyopathy, cancer, Holt-Oram syndrome, neurofibromatosis type 2, polycystic kidney disease and Alzheimer’s disease.
Read More
Cancer

New Raf kinase inhibitors disclosed in Enliven Therapeutics patent

Aug. 21, 2024
Enliven Therapeutics Inc. has divulged Raf kinase inhibitors reported to be useful for the treatment of cancer. An exemplified compound (Ex 5 [isomer B] pg 130) inhibited ERK phosphorylation in human melanoma A-375 cells (IC50=12.4 nM) in ELISA assays.
Read More
Infection

UK researchers describe new KARS inhibitors for parasitic infections

Aug. 21, 2024
Researchers at De Montfort University and Loughborough University have identified trifluoroquinazolines acting as lysyl tRNA synthetase (KARS) inhibitors reported to be useful for the treatment of parasitic infections.
Read More
Neurology/psychiatric

Takeda Pharmaceutical divulges new NLRP3 inflammasome inhibitors

Aug. 21, 2024
Takeda Pharmaceutical Co. Ltd. has synthesized NLRP3 inflammasome inhibitors reported to be useful for the treatment of neonatal-onset multisystem inflammatory disease (NOMID/CINCA), Muckle-Wells syndrome, familial cold autoinflammatory syndrome, Parkinson’s disease, Alzheimer’s disease, Huntington’s disease, amyotrophic lateral sclerosis and prion disease.
Read More
Infection

Rockefeller University patents new PL-PRO inhibitors for SARS-CoV-2

Aug. 21, 2024
Rockefeller University has disclosed non-structural protein 3 (nsp3; PL-PRO) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19).
Read More
Colon cancer illustration
Cancer

Baicalein found to sensitize colorectal cancer cells to radiotherapy

Aug. 21, 2024
Resistance to radiotherapy is a crucial factor in the outcome of colorectal cancer (CRC). The Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling pathway plays a key role in cell growth, differentiation, proliferation and immune function.
Read More
Photomicrograph of core biopsy of prostate gland showing histology of adenocarcinoma in patient with elevated PSA.
Cancer

Halda’s RIPTAC therapeutics offer novel mechanism to treat prostate cancer

Aug. 21, 2024
In a presentation at the American Chemical Society meeting, Halda Therapeutics Inc. described its androgen receptor (AR)-targeting RIPTAC (regulated induced proximity targeting chimera) therapeutics as a new class of heterofunctional small molecules designed to selectively kill cancer cells that express tumor-specific targeting protein (TIP) into a stable intracellular ternary complex with a protein essential for cell survival for the treatment of prostate cancer.
Read More
Illustration of intestines with inflammation
Gastrointestinal

Novel NLRP3 degrader ameliorates inflammatory symptoms in colitis models

Aug. 21, 2024
The nucleotide-binding oligomerization domain-like receptor pyrin domain containing 3 (NLRP3) inflammasome is an intracellular multiprotein complex that may be activated by exogenous or endogenous signals and is involved in the pathogenesis of several inflammatory disorders.
Read More
Previous 1 2 … 664 665 666 667 668 669 670 671 672 … 18114 18115 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 1, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 30, 2026
  • Illustration demonstrating gut-brain axis

    CINP 2026: Gut microbiota could predict antidepressant response

    BioWorld
    The gut microbiota may be altered in people with depression as a result of treatment. These microorganisms reorganize differently in individuals who respond to...
  • Brain made of chip and circuits

    Ascending BCI systems deepen national security, ethical concerns

    BioWorld
    Ready or not, the future has arrived. Novel AI and brain-computer interface (BCI) systems are no longer confined to the realm of science fiction. As an...
  • Black wavy lines forming an abstract sound wave.png

    Deep brain stimulation from the shallows: tomorrow’s BCI technology?

    BioWorld
    Deep brain stimulation (DBS) through implanted electrodes has enabled fundamentally new ways of treating certain disorders. More than 100,000 severely ill...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing